Read the full Original Article covered in this @GMA feature: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer https://t.co/rQ4b15lb0s #ASCO18 https://t.co/Bpg1k1WCf3
RT @NEJM: Original Article: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer (TAILORx) https://t.co/rQ4b15lb0s #…
RT @pozoparilli: Resultados del TAILORx impactará decisión terapéutica en muchos pacientes con cáncer de mama.El estudio comparó tratamient…
RT @NEJM: Original Article: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer (TAILORx) https://t.co/rQ4b15lb0s #…
#TAILORx article in @NEJM coincides with #ASCO18 plenary presentation. https://t.co/ftYuD6OBCt
RT @CDNCancerTrials: Great news for #breastcancer patients around the world! Many women with early-stage forms of the disease can forego ch…
Great news for #breastcancer patients around the world! Many women with early-stage forms of the disease can forego chemo, based on new study released today! #CCTG MAC.12 @queensuResearch @queensu @cancersociety #ASCO18 https://t.co/G6sJtXqUi6
RT @jesusanampa: momento histórico en el manejo de #cancer #MAMA Este estudio salvará a muchas mujeres de recibir quimioterapia en el futur…
Thanks for highlighting, @ESchattner Fior the Twitterverse, the full @NEJM article on the @theNCI #TAILORx trial is here: https://t.co/BBeBrlBX3u https://t.co/kEqSkChiuE
@Isabelalor2015 Ya, pero es interesante el nuevo estudio y el hecho de que no se haga así en todos los sitios: https://t.co/Lqme85Aq44 Gracias!! 👍
New from @NEJM: New genomic test for one type of breast cancer analyzes expression of 21 genes to determine efficacy of some chemo therapies, allowing Drs to be more precise about for whom they recommend chemo. https://t.co/OQkjuIi1lf
Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer | NEJM https://t.co/r1xtpeYYIV
RT @HenrychihangFu1: A landmark study. Strength of the study: ~ 10,000 pts with median follow up of 90 mons. Weakness of clinical trial: it…
RT @DrLaurenNye: Here it is! NEJM paper reports results of chemo vs no chemo in part of the intermediate group which showed no benefit to c…
A landmark study. Strength of the study: ~ 10,000 pts with median follow up of 90 mons. Weakness of clinical trial: it took so many participants (pts) so many years. Thus, hundred thousands of pts May have been over treated. https://t.co/GLKDCLmmjz
RT @NEJM: Original Article: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer (TAILORx) https://t.co/rQ4b15lb0s #…
RT @NEJM: Original Article: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer (TAILORx) https://t.co/rQ4b15lb0s #…
RT @NEJM: Original Article: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer (TAILORx) https://t.co/rQ4b15lb0s #…
RT @doctorpemm: #ASCO18 Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer | @NEJM #TAILORx #bcsm https://t.co/vi…
RT @drhuerta: @cesarsanz3 Con gusto, aquí está https://t.co/wdlarPfASA
RT @ESteyerberg: A positive result from the TAILORx trial is that it will contribute to reducing adjuvant chemotherapy in breast cancer. At…
RT @ESteyerberg: A positive result from the TAILORx trial is that it will contribute to reducing adjuvant chemotherapy in breast cancer. At…
RT @maxdieterich: Endlich: auch die Gruppe mit mittleren Risiko des #oncotypedx #Genexpressiontest profitiert NICHT von der #Chemotherapie…
I see research help my patients all the time...but this one helps my family personally. https://t.co/QDR7U5aDWW
RT @DukeHFDoc: Proud of my wife Claire on on the publication of TAILORx results in @NEJM today-immediate implications for vast numbers of b…
RT @Senology: Adjuvant endocrine therapy and chemoendocrine therapy have similar efficacy in patients with hormone-receptor–positive, HER2-…
RT @NEJM: Original Article: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer (TAILORx) https://t.co/rQ4b15lb0s #…
Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer | NEJM https://t.co/FPvdyWDRFK
RT @NEJM: Original Article: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer (TAILORx) https://t.co/rQ4b15lb0s #…
RT @DrLaurenNye: Here it is! NEJM paper reports results of chemo vs no chemo in part of the intermediate group which showed no benefit to c…
A positive result from the TAILORx trial is that it will contribute to reducing adjuvant chemotherapy in breast cancer. At least three limitations should be recognized however https://t.co/IP9dNTTJle @bds_lumc
RT @NEJM: Original Article: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer (TAILORx) https://t.co/rQ4b15lb0s #…
RT @NEJM: Original Article: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer (TAILORx) https://t.co/rQ4b15lb0s #…
RT @DrTanWP: Hopefully one day #biomarkers for #ProstateCancer can guide therapy. https://t.co/0CfDkuPb7g
Hopefully one day #biomarkers for #ProstateCancer can guide therapy. https://t.co/0CfDkuPb7g
RT @NEJM: Original Article: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer (TAILORx) https://t.co/rQ4b15lb0s #…
RT @HH_Oncodr: Kudos to Dr Joe Sparano and the #TAILORx team #asco18. And to co-author Dr @DToppmeyer, #BreastCancer leader @RutgersCancer.…
RT @NEJM: Original Article: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer (TAILORx) https://t.co/rQ4b15lb0s #…
RT @drhuerta: @cesarsanz3 Con gusto, aquí está https://t.co/wdlarPfASA
No all Breast CA benefits from Chemo https://t.co/ONgAnrN0Nl
@cesarsanz3 Con gusto, aquí está https://t.co/wdlarPfASA
RT @NEJM: Original Article: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer (TAILORx) https://t.co/rQ4b15lb0s #…
#TAILORx results out. #Breastcancer #bcsm: even intermediate risk patients on #oncotype score could have endocrine therapy alone without added benefit from #chemotherapy https://t.co/AdZgURdy4d
RT @NEJM: Original Article: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer (TAILORx) https://t.co/rQ4b15lb0s #…
RT @HenryKuerer: MORE info: Chemotherapy benefit for invasive disease–free survival varied with the combination of recurrence score and age…
RT @NEJM: Original Article: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer (TAILORx) https://t.co/rQ4b15lb0s #…
RT @NEJM: Original Article: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer (TAILORx) https://t.co/rQ4b15lb0s #…
RT @NEJM: Original Article: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer (TAILORx) https://t.co/rQ4b15lb0s #…
RT @NEJM: Original Article: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer (TAILORx) https://t.co/rQ4b15lb0s #…
@nikolabowden @whereisdaz I think I saw that this is the paper https://t.co/BUgXKE3j62
RT @NEJM: Original Article: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer (TAILORx) https://t.co/rQ4b15lb0s #…
A sweeping study found that many women with the most common kind of early-stage breast cancer don't need chemo: https://t.co/1jj5Q23Pjh
RT @doctorpemm: #ASCO18 Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer | @NEJM #TAILORx #bcsm https://t.co/vi…
RT @pozoparilli: Resultados del TAILORx impactará decisión terapéutica en muchos pacientes con cáncer de mama.El estudio comparó tratamient…
RT @GenomicHealth: .@NEJM publication on the long-awaited results of the #TAILORx study of #Oncotype DX, the largest ever breast cancer tre…
RT @pozoparilli: Resultados del TAILORx impactará decisión terapéutica en muchos pacientes con cáncer de mama.El estudio comparó tratamient…
RT @patriciaclarkmd: TAILORx: 21-gene assay may identify up to 85% of women with early breast cancer who can be spared adjuvant chemotherap…
多くの初期の乳がんは化学療法を要しない https://t.co/GeES3VllgT TAILORx原論文 https://t.co/uzylfh0L8C
RT @NEJM: Original Article: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer (TAILORx) https://t.co/rQ4b15lb0s #…
Latest discovery from the ASCO meeting on Oncotype DX® Breast Recurrence Score and the likelihood of dangerous breast cancer. https://t.co/19PETWOJmB https://t.co/v6ISvzxN2n
Groundbreaking study: 70% of patients who are diagnosed with the most common form of breast can safely avoid chemotherapy! https://t.co/9X8GhjRcaQ
Groundbreaking study: 70% of patients who are diagnosed with the most common form of breast can safely avoid chemotherapy! https://t.co/oxrnI7glXd
RT @tdcil: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer | NEJM https://t.co/FPbvgPBAHQ
RT @KirstinOConnor_: BIG NEWS for the fight against breast cancer. No more Chemo for about 70% of women with early stage cancer. Study—->…
RT @NEJM: Original Article: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer (TAILORx) https://t.co/rQ4b15lb0s #…
Adjuvant endocrine therapy and chemoendocrine therapy have similar efficacy in patients with hormone-receptor–positive, HER2-negative, axillary node–negative breast cancer with a midrange 21-gene recurrence score https://t.co/9RR5SfJEHR #breast #cancer #AS
RT @cengizhanozturk: Big potential clinical impact: Adjuvant endocrine therapy and chemoendocrine therapy had similar efficacy in women wit…
RT @Fraslin Cancer du sein: La chimiothérapie adjuvante guidée par un test d'expression de 21 gènes https://t.co/Emcz08CU5G
Seit Jahren gibt es Streit um die Gentests bei Brustkrebs, nun gibt es mehr Daten dazu. Achtung: Dies ist kein Werbetweet, aber hier gibt es den Zugang zum Paper zum Nachgucken. https://t.co/0Z89cgBpX1
RT @NEJM: Original Article: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer (TAILORx) https://t.co/rQ4b15lb0s #…
RT @pozoparilli: Resultados del TAILORx impactará decisión terapéutica en muchos pacientes con cáncer de mama.El estudio comparó tratamient…
Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer | NEJM https://t.co/wHfHBcQx3m Most Women With Early Stage Breast Cancer Can Forgo Chemotherapy When Guided by a Diagnostic Test | ASCO https://t.co/Pl3ZiRvxs0
RT @NEJM: Original Article: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer (TAILORx) https://t.co/rQ4b15lb0s #…
Important results from TAILORx study, hopefully funding for this will continue!! https://t.co/5C58qE3FFW
RT @patriciaclarkmd: TAILORx: 21-gene assay may identify up to 85% of women with early breast cancer who can be spared adjuvant chemotherap…
Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer | NEJM https://t.co/nqV5UsUkoW #asco18
Según estudio @NEJM muchas mujeres con #cancerDeMama común pueden evitar #quimioterapia de forma segura By Joseph A. Sparano @EinsteinMed Vía @cnnbrk https://t.co/amn5HerLhH ✍️https://t.co/1F6UKySTR1 👁️👍@secpal_ @AECPAL_ @sacpaandalucia @PaliativosUGR @_R
RT @patriciaclarkmd: TAILORx: 21-gene assay may identify up to 85% of women with early breast cancer who can be spared adjuvant chemotherap…
RT @pozoparilli: Resultados del TAILORx impactará decisión terapéutica en muchos pacientes con cáncer de mama.El estudio comparó tratamient…
RT @KirstinOConnor_: BIG NEWS for the fight against breast cancer. No more Chemo for about 70% of women with early stage cancer. Study—->…
RT @BeckyAlleyneMD: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer | NEJM https://t.co/eAOyzoKraS
Here it is! NEJM paper reports results of chemo vs no chemo in part of the intermediate group which showed no benefit to chemo. Sub-analysis still raises question of maybe a small benefit in those < 50y/o, but overall fantastic news! So I ask, what is y
BIG NEWS for the fight against breast cancer. No more Chemo for about 70% of women with early stage cancer. Study—-> https://t.co/co28AXFY1F https://t.co/a4Ht7N1Jz0
RT @NEJM: Original Article: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer (TAILORx) https://t.co/rQ4b15lb0s #…
RT @NEJM: Original Article: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer (TAILORx) https://t.co/rQ4b15lb0s #…
Certainly a practice changing study for breast Ca pts #ASCO18 #TAILORx #bcsm https://t.co/VjX2dIliDy
RT @NEJM: Original Article: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer (TAILORx) https://t.co/rQ4b15lb0s #…
RT @skathire: Using a gene-expression signature test to avoid unnecessary adjuvant chemo in BrCa! Pretty striking results, 10K women rando…
Endlich: auch die Gruppe mit mittleren Risiko des #oncotypedx #Genexpressiontest profitiert NICHT von der #Chemotherapie beim HR+ HER2- nodal negativen #mammakarzinom Ein weiterer Schritt in Richtung Deeskalation #asco2018 https://t.co/2vBYLEiLyS
Unfortunately this trial (a triumph of marketing) asks the wrong question. Of course the benefit of chemo in a very low risk group is negligible (especially if 20% of get chemo). The question is whether this test provides better information than other che
@VinayPrasadMD what's your take on this RCT of gene-expression test guided treatment for breast cancer? Thx #not_trolling #genuinely_curious_on_your_take https://t.co/zXDg6dDikh